SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Prior treatment

• Participants with prior anti-CD38 treatment: (a) administered less than 9 months before randomization or, (b) intolerant to the anti-CD38 previously received
• Prior therapy with pomalidomide
• Participants diagnosed or treated for another malignancy within 3 years prior to randomization with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, and in situ malignancy, or low risk prostate cancer after curative therapy
• Concomitant plasma cell leukemia

Other illness

• Significant cardiac dysfunction
• Known acquired immunodeficiency syndrome (AIDS)-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment
• Know active Hepatitis A infection. Current active or chronic hepatitis B (HBV) or hepatitis C (HCV) infection. Participants with chronic HBV or HCV disease that is controlled under antiviral therapy are allowed.

Other

• Primary refractory multiple myeloma participants
• Participants with inadequate biological tests.
• Active primary amyloid light -chain amyloidosis
• Women of childbearing potential or male participant with women of childbearing potential who do not agree to use highly effective method of birth control
  • The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

• Participants with multiple myeloma who have received at least one prior line of anti-myeloma therapy, which must include lenalidomide and a proteasome inhibitor given alone or in combination.
• Measurable serum M-protein (≥ 0.5 g/dL) and/or urine M-protein (≥ 200 mg/24 hours) and/or serum free light chain (FLC) assay (Involved FLC assay ≥10 mg/dL and abnormal serum FLC ratio (\<0.26 or \>1.65)).